Crispr Therapeutics AG logo

Crispr Therapeutics AG (CRSP)

Market Closed
7 Nov, 20:00
NASDAQ (NMS) NASDAQ (NMS)
$
55. 12
-1.49
-2.63%
$
5.82B Market Cap
- P/E Ratio
0% Div Yield
2,932,258 Volume
-2.71 Eps
$ 56.61
Previous Close
Day Range
52.42 55.22
Year Range
30.04 78.48
Want to track CRSP and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 92 days
Should CRSP Stock Be in Your Portfolio Pre-Q3 Earnings?

Should CRSP Stock Be in Your Portfolio Pre-Q3 Earnings?

CRISPR Therapeutics is likely to witness an earnings beat as Casgevy sales climb and new CAR-T and in-vivo programs advance.

Zacks | 4 days ago
CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It

CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It

Recently, Zacks.com users have been paying close attention to CRISPR Therapeutics (CRSP). This makes it worthwhile to examine what the stock has in store.

Zacks | 1 week ago
CRISPR Therapeutics AG (CRSP) Expected to Beat Earnings Estimates: Should You Buy?

CRISPR Therapeutics AG (CRSP) Expected to Beat Earnings Estimates: Should You Buy?

CRISPR Therapeutics (CRSP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks | 1 week ago
CRISPR Therapeutics AG (CRSP) Sees a More Significant Dip Than Broader Market: Some Facts to Know

CRISPR Therapeutics AG (CRSP) Sees a More Significant Dip Than Broader Market: Some Facts to Know

CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $74.89, moving 2.46% from the previous trading session.

Zacks | 1 month ago
CRISPR Therapeutics (CRSP) Surges 8.7%: Is This an Indication of Further Gains?

CRISPR Therapeutics (CRSP) Surges 8.7%: Is This an Indication of Further Gains?

CRISPR Therapeutics (CRSP) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zacks | 1 month ago
CRISPR Therapeutics AG (CRSP) Stock Falls Amid Market Uptick: What Investors Need to Know

CRISPR Therapeutics AG (CRSP) Stock Falls Amid Market Uptick: What Investors Need to Know

CRISPR Therapeutics AG (CRSP) reached $67.74 at the closing of the latest trading day, reflecting a -6.98% change compared to its last close.

Zacks | 1 month ago
Wall Street Analysts See CRISPR Therapeutics (CRSP) as a Buy: Should You Invest?

Wall Street Analysts See CRISPR Therapeutics (CRSP) as a Buy: Should You Invest?

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?

Zacks | 1 month ago
CRISPR Therapeutics AG (CRSP) Stock Slides as Market Rises: Facts to Know Before You Trade

CRISPR Therapeutics AG (CRSP) Stock Slides as Market Rises: Facts to Know Before You Trade

In the most recent trading session, CRISPR Therapeutics AG (CRSP) closed at $51.81, indicating a -3.5% shift from the previous trading day.

Zacks | 1 month ago
CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It

CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It

CRISPR Therapeutics (CRSP) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Zacks | 2 months ago
CRISPR Therapeutics Gains 41.4% in 3 Months: How to Play the Stock

CRISPR Therapeutics Gains 41.4% in 3 Months: How to Play the Stock

CRSP surges 41.4% in three months, fueled by promising CTX310 study data and accelerating Casgevy sales.

Zacks | 2 months ago
Investors Heavily Search CRISPR Therapeutics AG (CRSP): Here is What You Need to Know

Investors Heavily Search CRISPR Therapeutics AG (CRSP): Here is What You Need to Know

CRISPR Therapeutics (CRSP) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Zacks | 2 months ago
Upgrading Crispr Therapeutics To Hold Ahead Of A Catalyst-Rich 2H 2025

Upgrading Crispr Therapeutics To Hold Ahead Of A Catalyst-Rich 2H 2025

CRISPR Therapeutics' recent in vivo CTX310 data validates its technology, marking a fundamental shift and supporting a rating upgrade from Sell to Hold. CASGEVY sales are growing but remain unprofitable, with ex vivo therapy complexity limiting mass adoption and reinforcing the need for scalable in vivo solutions. Upcoming high-stakes clinical readouts for CTX310, CTX112, and CTX131 could significantly impact CRSP's valuation, warranting a cautious, milestone-driven approach.

Seekingalpha | 2 months ago
Loading...
Load More